Improvement of national blood safety profile: effect of contract fractionation of plasma in resource limited countries, the Moroccan experience

Boulahdid, S.; Benahadi, A.; Adouani, B.; Laouina, A.; Mehdaoui, Fatna El; Mokhtari, A.; Soulaymani, Abdelmajid; Hajjout, K.; Alami, Reza

doi:10.1111/hae.12482

Cited by 5 publications

(5 citation statements)

References 5 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although plasma fractionation activities may be expensive, some countries have reported substantial savings associated with implementing fractionation activities of normally discarded recovered plasma, provided a convenient product balance is achieved. Beneficial impacts on the quality and safety of all blood components through the introduction of the concept of GMPs have also been observed [6,[13][14][15].…”

Section: Contract Fractionation: a Pragmatic Way To Gomentioning

confidence: 99%

“Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed!

Burnouf

Seghatchian

2014

Transfusion and Apheresis Science

View full text Add to dashboard Cite

In the late 1980s, following the human immunodeficiency virus (HIV) epidemic and transfusion-transmitted infections from plasma-derived coagulation factor concentrates to hemophiliacs, many “advanced thinkers” claimed that plasma-derived products would be completely replaced by the year 2000 by safe recombinant products in most developed countries. However, things have not turned out that way, due to both the continual progress witnessed in plasma fractionation and viral-reduction technologies and technical difficulties still being encountered in developing more cost-effective non-immunogenic, fully active recombinant therapeutic proteins. Accordingly, plasma fractionation remains a reasonably healthy industry worldwide, with an ever-increasing volume of plasma fractionated each year to meet the demands for safe and effective plasma-derived medicines at the global level. While high-income countries currently have generally good access to a panel of plasma-derived and recombinant products, desperate shortages of fractionated plasma products remain in developing economies,and patients still have to be treated inadequately. The steady development of the collection of whole blood in developing economies, to gradually cover the recognized needs for red blood cell concentrates, generates an increasing volume of recovered plasma that is currently wasted. Incentives are therefore high for those countries to consider fractionating such plasma as a means of enhancing their supply of products to treat patients, thereby also decreasing the level of dependence on imported products. Challenges of local plasma fractionation in developing economies are high, in a context where the technological and regulatory sophistication of the plasma fractionation industry is often underestimated, and the blood supply may be exposed to emerging infectious agents. In parallel, plasma product quality requirements and drivers are evolving in developed economies as is the awareness of clinicians to newer uses of products such as intravenous immunoglobulins, somewhat deviating from what currently remain the basic needs of developing countries in terms of affordable safe plasma products. Global market trends for plasma-derived products, through plasma fractionation, are still increasing, despite increasing use of recombinant products, and attention is being focused on the five Ws of the fractionation field: which products; where; when; what and how much; and who will be the main suppliers?

show abstract

Section: Contract Fractionation: a Pragmatic Way To Gomentioning

confidence: 99%

“Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed!

Burnouf

Seghatchian

2014

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

“…Over the last two decades, blood safety procedures in Morocco have undergone a great deal of improvement. [4][5][6] The measures taken to prevent bacterial contamination include the introduction and enforcement of disinfection procedures at the donor antecubital fossa (AF) and the introduction of a diversion pouch (DP) to collect the first 20 to 30 mL of blood. This system has been shown to reduce the risk of transmitting bacteria to entire blood units and to individual blood components.…”

Section: Introductionmentioning

confidence: 99%

Skin flora and bacterial contamination of diversion pouch and recovered platelet components in Moroccan blood donors

Mehdaoui

Benajiba²,

Boulahdid³

et al. 2020

Transfusion Medicine

View full text Add to dashboard Cite

Objective: The objective of this study was to evaluate bacterial reduction procedures used during whole-blood donations in Morocco. Background: Bacterial contamination still poses serious challenges to blood safety, especially in countries with limited resources. Methods: In the first part of this study, we analysed 233 swab samples taken from blood donors' antecubital fossa. After donation, a second batch of samples was analysed from the diversion pouches of corresponding donors. In addition, we searched for the prevalence of bacterial contamination in 568 randomly chosen platelet components at their expiration date in order to control for the entire blood unit preparation process. Results: The most frequently found bacterial species at the antecubital fossa of healthy blood donors were coagulase-negative Staphylococcus, aerophilic Corynebacterium, Staphylococcus aureus, Bacillus sp. and Micrococcus sp. After donation, 5.15% of the diversion pouches were contaminated with bacterial species, the most notable being Bacillus sp., aerophilic Corynebacterium, coagulase-negative Staphylococcus, Staphylococcus aureus and Pseudomonas aeruginosa. Of 568 platelet components, 18 were contaminated with three bacterial species: Bacillus sp., coagulase-negative Staphylococcus and Staphylococcus aureus. Conclusion: All three bacterial species found in platelet components were detected on the skin of blood donors. Serious measures need to be taken and enforced to ensure blood safety.

show abstract

“…Over the last 10 years blood safety in Morocco, achieved a great deal of improvement. 8 This study is the first of its kind in the country that monitored the prevalence of bacterial PCs contamination on day 2 after blood collection. For this purpose, a retrospective study, to determine the prevalence of bacterial contamination of PCs produced by Regional Center for Blood Transfusion (CRTS) of Rabat was conducted.…”

Section: Introductionmentioning

confidence: 99%

Retrospective Study of the Prevalence of Bacterial Contamination of Platelet Concentrates in Morocco

Mehdaoui¹,

Bouazzaoui²,

Soulaymani³

et al. 2020

JYP

View full text Add to dashboard Cite

Improvement of national blood safety profile: effect of contract fractionation of plasma in resource limited countries, the Moroccan experience

Cited by 5 publications

References 5 publications

“Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed!

“Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed!

Skin flora and bacterial contamination of diversion pouch and recovered platelet components in Moroccan blood donors

Retrospective Study of the Prevalence of Bacterial Contamination of Platelet Concentrates in Morocco

Contact Info

Product

Resources

About